文献速递肾移植

多发性骨髓瘤患者的肾移植结局

Kidney Transplant Outcomes of Patients With Multiple Myeloma.
PubMed 文献 · Kidney Int Rep · 2022-01-10

该研究回顾了1994年至2019年间11例多发性骨髓瘤患者接受的12次肾移植,中位随访40个月。移植后9次(75%)出现血液学进展,3例(25%)移植肾失功,5例(45.5%)在移植肾功能正常时死亡。接受硼替佐米治疗者总生存似更优,但复发仍常见,需更多研究确定获益人群。

要点

  • 多发性骨髓瘤患者肾移植后血液学进展常见,12次移植中9次(75%)出现进展。
  • 移植肾1年存活率82.5%、5年66%;无进展生存1年83.3%、3年55.6%、5年44.4%。
  • 接受硼替佐米者中位无进展生存未达到,未接受者为24个月(P=0.281)。

核心结论

  • 接受硼替佐米(移植前和/或移植后)的多发性骨髓瘤患者肾移植结局似乎更有利,但移植后复发仍常见,需更多研究确定谁从肾移植中获益。

研究设计与样本

  • 研究类型为回顾性队列研究,纳入1994年至2019年间接受肾移植的多发性骨髓瘤患者,共11例患者、12次移植。

主要发现

  • 移植时6次移植为严格完全缓解(CR)、2次为CR、2次为非常好的部分缓解(VGPR)、2次为部分缓解(PR)。
  • 中位随访40个月(最短-最长,5-92个月)后,9次移植(75%)出现血液学进展,3例移植肾(25%)失功,5例患者(45.5%)在移植肾功能正常时死亡。
  • 移植肾1年存活率82.5%、5年66%;队列无进展生存(PFS)1年83.3%、3年55.6%、5年44.4%。
  • 接受硼替佐米者(移植前和/或移植后)估计中位PFS未达到,从未接受硼替佐米者为24个月(P=0.281)。
  • 队列总生存(OS)1年81.8%、3年61.4%、5年61.4%;接受硼替佐米者OS 1年87.5%、3年72.9%、5年72.9%,从未接受硼替佐米者OS 1年66.7%、3年33.3%、5年33.3%(P=0.136);所有死亡均因血液学进展或治疗相关并发症。

关键数值与推荐

  • 移植时疾病状态:严格完全缓解6次、完全缓解2次、非常好的部分缓解2次、部分缓解2次。
  • 随访期间血液学进展9次(75%),移植肾失功3例(25%),移植肾功能正常时死亡5例(45.5%)。
  • 移植肾存活率1年82.5%、5年66%;无进展生存率1年83.3%、3年55.6%、5年44.4%;总生存率1年81.8%、3年61.4%、5年61.4%。
  • 接受硼替佐米者中位无进展生存未达到,未接受者为24个月(P=0.281);接受硼替佐米者总生存1年87.5%、3年72.9%、5年72.9%,未接受者1年66.7%、3年33.3%、5年33.3%(P=0.136)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Data on kidney transplantation (KTx) outcomes of patients with multiple myeloma (MM) are very limited. METHODS: We investigated the outcomes of patients with MM who underwent KTx between 1994 and 2019. RESULTS: A total of 12 transplants from 11 patients were included. At the time of KTx, 6 were classified as having stringent complete response (CR), 2 as CR, 2 as very good partial response (VGPR), and 2 as partial response (PR). With a median follow-up of 40 (minimum-maximum, 5-92) months after KTx, hematologic progression occurred in 9 transplants (75%). There were 3 grafts (25%) that failed, and 5 patients (45.5%) experienced death with functioning allografts. Graft survival at 1 and 5 years was 82.5% and 66%, respectively. Progression-free survival (PFS) rates of the cohort at 1, 3, and 5 years were 83.3%, 55.6%, and 44.4%, respectively. The estimated median PFS of patients who received bortezomib at any time (pre-KTx and/or post-KTx) was not reached, whereas it was 24 months for those who never received bortezomib (P = 0.281). Overall survival (OS) rates of the cohort at 1, 3, and 5 years were 81.8%, 61.4%, and 61.4%, respectively. OS of patients who received bortezomib at any time was 87.5%, 72.9%, and 72.9%, and that for those who never received bortezomib was 66.7%, 33.3%, and 33.3% (P = 0.136). All deaths occurred owing to hematologic progression or treatment-related complications. CONCLUSION: Kidney transplant outcomes of patients with myeloma who received bortezomib before or after KTx seem to be more favorable. Nevertheless, relapse after KTx in MM is still common. More studies are needed to better determine who benefits from a KTx.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Heybeli C, Bentall AJ, Alexander MP, et al. Kidney Transplant Outcomes of Patients With Multiple Myeloma. Kidney Int Rep. 2022. PMID: 35497786. doi:10.1016/j.ekir.2022.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。